SAVA - Cassava Sciences, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Cassava Sciences, Inc.

7801 North Capital of Texas Highway
Suite 260
Austin, TX 78731
United States
512-501-2444
http://www.cassavasciences.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees9

Key Executives

NameTitlePayExercisedYear Born
Mr. Remi BarbierFounder, Chairman, CEO & Pres881.99kN/A1960
Mr. Eric J. SchoenChief Financial Officer181.75kN/A1968
Dr. Nadav FriedmannCOO, Chief Medical Officer & Director320kN/A1943
Dr. George ThorntonSr. VP of TechnologyN/AN/AN/A
Mr. Michael ZamlootSr. VP of Technical OperationsN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Cassava Sciences, Inc., a clinical-stage drug development company, develops drugs for nervous system disorders. The company's lead therapeutic product candidate PTI-125, a small molecule drug that is in Phase II clinical trial for the treatment of Alzheimer's disease. It is also developing PTI-125Dx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was founded in 1998 and is based in Austin, Texas.

Corporate Governance

Cassava Sciences, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.